XORTX Therapeutics Inc. (XRTX.V)
- Previous Close
3.4200 - Open
3.6100 - Bid 3.4800 x --
- Ask 3.6200 x --
- Day's Range
3.5000 - 3.6200 - 52 Week Range
2.6500 - 89.9100 - Volume
1,600 - Avg. Volume
14,716 - Market Cap (intraday)
10.308M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8900 - Earnings Date Aug 14, 2024 - Aug 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
www.xortx.comRecent News: XRTX.V
Performance Overview: XRTX.V
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XRTX.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XRTX.V
Valuation Measures
Market Cap
9.93M
Enterprise Value
4.70M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.91
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.50
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.00%
Return on Equity (ttm)
-57.92%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-3.34M
Diluted EPS (ttm)
-1.8900
Balance Sheet and Cash Flow
Total Cash (mrq)
3.84M
Total Debt/Equity (mrq)
0.56%
Levered Free Cash Flow (ttm)
-2.96M